Biomarkers Of Lung InVolvement In ASMD (BOLIVIA)

The goal of this study is to characterize ASMD patients' breath profile, exhaled breath and condensate as compared to healthy controls to identify specific volatile and non-volatile compounds that reflect inflammatory processes, fibrotic processes or sphingolipid accumulation in the lungs.

Participants will be provided exhaled breath samples in three ways (breath profile, volatile compounds and condensate). ASMD patients will be compared to age- and sex-matched healthy controls.

Study Overview

• Status: Recruiting
• Conditions: Asmd, Visceral Type
• Intervention / Treatment: Diagnostic test: eNose; Diagnostic test: Volatile exhaled breath sample; Diagnostic test: Condensate sample

Detailed Description

Rationale: Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease in which sphingomyelin accumulates due to a deficiency of the enzyme acid sphingomyelinase. The most common manifestations of the chronic visceral subtype of this disease are hepatosplenomegaly and interstitial lung disease (ILD). Currently, enzyme replacement therapy is under investigation and will likely become available in the near future. The first results indicate that pulmonary involvement may be responsive to treatment. In order to identify those patients that will potentially benefit from therapy, biomarkers for lung injury can be helpful. Compounds measured in exhaled breath and exhaled breath condensate are extensively studied in common lung diseases and increasingly in ILD. These compounds are of interest since they provide information directly form the lung compartment and are collected non-invasively.

Objective: Our aim is to characterize ASMD patients' breath profile, exhaled breath and condensate as compared to healthy controls to identify specific volatile and non-volatile compounds that reflect inflammatory processes, fibrotic processes or sphingolipid accumulation in the lungs.

Study design: This study comprises a cross-sectional case-control part and a prospective cohort part. In the cross-sectional part, exhaled breath samples with volatile and non-volatile compounds of ASMD patients and healthy controls will be collected. After potential biomarkers are identified in the cross-sectional part, patients will enter the longitudinal part in which the prognostic and monitoring value of these markers will be evaluated using clinical parameters.

Study population: ASMD patients ≥ 12 years of age with a confirmed diagnosis of the chronic visceral type will be included as well as age-, sex- and smoking status-matched healthy controls with a ratio of 1:3.

Main study parameters/endpoints: Inflammatory markers, fibrotic markers and markers of sphingolipid accumulation will be measured in exhaled breath. Breath profiles will be measured with eNose, volatile compounds will be measured with GC-MS and non-volatile compounds will be measured in exhaled breath condensates using UPLC-MS/MS.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Sampling of exhaled breath yields no risk: at most, patients might suffer from dizziness or mild dyspnea. Patients will not directly benefit from participation in the study. We aim to identify biomarkers reflecting lung involvement of ASMD and in that respect the results of the study may improve clinical care in the future for the patients participating in the study or any ASMD patient with similar characteristics.

• Study Type: Interventional
• Enrollment (Estimated): 68
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Eline CB Eskes, MD; Phone Number: 003125669111; Email: e.c.eskes@amsterdamumc.nl

Study Locations

• Netherlands
  • Noord-Holland
    • Amsterdam, Noord-Holland, Netherlands, 1105 AZ
      • Recruiting
      • Amsterdam UMC
      • Contact: Eline CB Eskes, MD; Phone Number: 0205669111; Email: e.c.eskes@amsterdamumc.nl
      • Sub-Investigator: Eline CB Eskes, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Patients:

• The patient has a biochemical and genetically confirmed diagnosis of the chronic visceral subtype of ASMD
• The patient is willing and able to provide written informed consent prior to the study-related procedure.
• The patient is ≥ 12 years of age

Healthy controls:

• The individual is willing and able to provide written informed consent prior to the study-related procedure
• The individual is ≥ 16 years of age
• General good health as determined by medical history

Exclusion Criteria:

Patients:

• Inability to adhere to the study protocol
• When a patient is not able to complete a spirometry test, the eNose sample will not be collected.

Healthy controls:

• Medical history of (systemic) disease for which medication was necessary
• Inability to adhere to the study protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Healthy controls	Diagnostic test: eNose; Collection of breath profile with eNose; Diagnostic test: Volatile exhaled breath sample; Collection of exhaled breath in Tedlar bag; Diagnostic test: Condensate sample; Collection of exhaled breath condensate with EcoScreen
Other: ASMD patients	Diagnostic test: eNose; Collection of breath profile with eNose; Diagnostic test: Volatile exhaled breath sample; Collection of exhaled breath in Tedlar bag; Diagnostic test: Condensate sample; Collection of exhaled breath condensate with EcoScreen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Markers of inflammation, fibrosis or sphingolipid accumulation in exhaled breath	Markers of inflammation, fibrosis or sphingolipid accumulation in exhaled breath of ASMD patients. Since this is an explorative study these markers cannot be defined in advance.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biomarkers with monitoring or prognostic value in ASMD	Biomarkers with monitoring or prognostic value in ASMD patients in a longitudinal study design. Since this is an explorative study these markers cannot be defined in advance.	10 years

Collaborators and Investigators

• Sponsor: Eline C. B. Eskes
• Investigators: Principal Investigator: Carla EM Hollak, MD, PhD, prof, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study record dates

Study Major Dates

• Study Start (Actual): December 5, 2022
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: June 6, 2023
• First Submitted That Met QC Criteria: June 19, 2023
• First Posted (Actual): June 22, 2023

Study Record Updates

• Last Update Posted (Actual): June 22, 2023
• Last Update Submitted That Met QC Criteria: June 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Lymphatic Diseases; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Lipid Metabolism Disorders; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Lipidoses; Lipid Metabolism, Inborn Errors; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Niemann-Pick Diseases; Niemann-Pick Disease, Type B
• Other Study ID Numbers: 2020_298#B2021154

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Research data will be submitted as articles to peer-reviewed journals. Also, an abstract of our research data reporting our findings will be submitted for presentations on scientific, public and/or patient organization meetings for oral presentation(s).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No